Tag Archives: R&D Productivity

Positive Impact Of External Sourcing On Pharma R&D Productivity
December 16, 2016

Pharma R&D productivity continues to be a critical issue for the industry. Making smart investments in R&D requires an understanding of the risk and return drivers across the product development cycle, as well as some good fortune. This week the

Leave a comment

External Innovation: Force Multiplier For R&D
June 26, 2015

External models of R&D innovation are the rage in Pharma today, as they should be – the future of our industry depends on a great deal more rather than less collaboration. In a very healthy way, lots of experiments are


A Billion Here, A Billion There: The Cost Of Making A Drug Revisited
November 21, 2014

The cost of making a new drug has grown to nearly $2.6B, according to the latest and greatest from Tufts Center for the Study of Drug Development (here).  That’s a big and almost unfathomable number.  Critics immediately pounced on it,


Talent Acquisition: Pharma Is The Lifeblood Of Biotech
May 19, 2014

Startup Biotechs need bigger drug companies for lots of things, including R&D collaborations, investments, non-dilutive funding, and eventual liquidity via M&A. The health of today’s ecosystem depends on biotech and pharma working together. But one of the most important and


Risk: A User’s Guide For Drug Developers
May 14, 2014

In my last post, I argued that the key to the success – and perhaps even the survival – of the biopharma industry is to excel at risk management. We are in an inherently risky business, where there are thousands of


Leveraging Nature’s Experiments: Mitigating Drug Discovery Risks Through Human Genetics
May 8, 2014

Extreme clinical phenotypes caused by rare genetic variations have been the basis of some of the most exciting drug targets in today’s pharmaceutical pipeline: PCSK9 in cholesterol, sclerostin in bone diseases, Nav1.7 for pain.  The rare gene signatures underlying these


Transformational Late Stage Drugs Delivered Through Deal-Making
March 21, 2014

Today’s biopharma industry has a richer and more exciting late stage pipeline of compelling new therapeutics than its had in years, drawing lots of enthusiasm from analysts and investors.  Goldman Sachs (GS) recently published a report on the “10 drugs


Unlocking The Promise Of Biotech Startups: Learnings From Mars, Goliath, and Evolution
March 5, 2014

As an early stage biotech investor, the future of the industry and its structure are clearly important things to think about – especially since most of the drug programs our new startups are working on won’t get launched, if they


If I Were A Big Pharma Head of R&D…
August 5, 2013

The Pharma R&D model is certainly suffering, and the industry’s pandemic sickness is best embodied by “Eroom’s law” of ever-decreasing R&D productivity. But it’s a lot easier to diagnose this disease than it is to prescribe a medicine. In fairness,